Genomic Profiling - A Need for Clinical Decision? -Case Reports.

Autor: Ciurea AM; Department of Oncology, University of Medicine and Pharmacy of Craiova, Romania., Schenker M; Department of Oncology, University of Medicine and Pharmacy of Craiova, Romania., Ciofiac CM; Doctoral School, Department of Radiology and Medical Imaging, University of Medicine and Pharmacy of Craiova., Streba L; Department of Oncology, University of Medicine and Pharmacy of Craiova, Romania., Schenker R; Psychology Department, Sf Nectarie Oncology Center, Craiova, Romania., Streba CT; Department of Pulmonology, University of Medicine and Pharmacy of Craiova, Romania.
Jazyk: angličtina
Zdroj: Current health sciences journal [Curr Health Sci J] 2023 Jul-Sep; Vol. 49 (3), pp. 467-473. Date of Electronic Publication: 2023 Sep 30.
DOI: 10.12865/CHSJ.49.03.22
Abstrakt: Cancer is still an important health issue worldwide due to increased incidence and mortality. Personalized medicine is the future of cancer treatment. Development in technology improved technical skills in DNA/RNA sequencing. NGS technology in solid-tumor samples can describe DNA or RNA analysis by including the entire genome to detect clinical relevant mutations. Genetic results may be considered having a dynamic impact because of heterogenous molecular alterations depending of time and treatment influence. We conducted a retrospective study of all NGS tests made in the last five years for the patients from 'Sf. Nectarie' Oncology Center, Craiova, Romania. We selected three relevant clinical cases where NGS analysis was performed and the results changed the perspective of the clinical decision. Our aim is to evaluate the importance of NGS results in clinical approach. Although medicine known an important development during the last decades, only a few patients can benefit of advanced personalized treatments. It is still hard to identify the alterations or gene mutations because of genetic tests are not easily available and only a small proportion of patients carries genetic alterations.
Competing Interests: None to declare.
(Copyright © 2023, Medical University Publishing House Craiova.)
Databáze: MEDLINE
Externí odkaz: